| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CTSD |
| Uniprot No | P07339 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 67-403aa |
| 氨基酸序列 | IPEVLKNYMDAQYYGEIGIGTPPQCFTVVFDTGSSNLWVPSIHCKLLDIACWIHHKYNSDKSSTYVKNGTSFDIHYGSGSLSGYLSQDTVSVPCQSASSASALGGVKVERQVFGEATKQPGITFIAAKFDGILGMAYPRISVNNVLPVFDNLMQQKLVDQNIFSFYLSRDPDAQPGGELMLGGTDSKYYKGSLSYLNVTRKAYWQVHLDQVEVASGLTLCKEGCEAIVDTGTSLMVGPVDEVRELQKAIGAVPLIQGEYMIPCEKVSTLPAITLKLGGKGYKLSPEDYTLKVSQAGKTLCLSGFMGMDIPPPSGPLWILGDVFIGRYYTVFDRDNNR |
| 预测分子量 | 63.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CTSD(组织蛋白酶D)重组蛋白的3篇虚构参考文献示例，涵盖不同研究方向：
---
1. **标题**：*High-yield expression and purification of recombinant human CTSD in Escherichia coli for functional studies*
**作者**：Smith, J.R., et al.
**摘要**：本研究报道了通过密码子优化和融合标签(His-tag)策略，在大肠杆菌中高效表达可溶性重组人CTSD蛋白。优化后的蛋白经亲和层析纯化后，酶活性分析显示其具有与天然CTSD相似的pH依赖性蛋白酶活性，为大规模制备研究用CTSD提供了可行方案。
2. **标题**：*Comparative analysis of CTSD glycosylation patterns in yeast and mammalian expression systems*
**作者**：Li, X., & Müller, C.
**摘要**：通过毕赤酵母和CHO细胞系统表达重组CTSD，对比发现哺乳动物系统产生的CTSD糖基化修饰更接近天然形式，且糖链结构显著影响其在溶酶体环境中的稳定性。研究为CTSD的疾病相关功能研究提供了表达系统选择依据。
3. **标题**：*Crystal structure of recombinant CTSD in complex with pepstatin A reveals substrate-binding mechanisms*
**作者**：Garcia, F., et al.
**摘要**：利用昆虫细胞表达系统获得高纯度重组CTSD，并通过X射线晶体学首次解析其与抑制剂胃酶抑素A的复合物结构。研究发现Asp231和Thr234残基在底物识别中起关键作用，为设计特异性CTSD抑制剂提供了结构基础。
---
*注：以上文献为示例性内容，实际研究中请通过学术数据库检索真实文献。*
Cathepsin D (CTSD) is a lysosomal aspartic protease belonging to the peptidase A1 family. It plays a critical role in protein degradation within lysosomes, maintaining cellular homeostasis by breaking down intracellular and endocytosed proteins. Beyond its catabolic function, CTSD is involved in regulating apoptosis, cell proliferation, and immune responses. Dysregulation of CTSD has been linked to various diseases, including cancer, neurodegenerative disorders (e.g., Alzheimer’s and Parkinson’s), and lysosomal storage diseases. Its overexpression in tumors is associated with enhanced invasion and metastasis, while deficiencies contribute to neuronal ceroid lipofuscinosis.
Recombinant CTSD protein is produced using genetic engineering techniques to express and purify the enzyme in heterologous systems like *E. coli*, yeast, or mammalian cells. This approach ensures high purity, consistency, and scalability compared to isolating the protein from natural sources. Mammalian expression systems are often preferred to achieve proper post-translational modifications, such as glycosylation, which are essential for enzymatic activity. Recombinant CTSD retains proteolytic functionality, enabling researchers to study its structure, substrate specificity, and interaction with inhibitors.
The availability of recombinant CTSD has advanced drug discovery, particularly in developing protease inhibitors for cancer and neurodegenerative diseases. It also serves as a tool for diagnostic assays, biomarker studies, and understanding disease mechanisms. Ongoing research focuses on its dual role as both a protective and pathogenic agent, highlighting its therapeutic potential in modulating lysosomal pathways or targeting aberrant activity in pathological conditions.
×
